Enzyme replacement therapy for a severely affected premature boy (birthweight: 2380 g,GA:36 weeks) with hypophosphatasia was attempted by infusions of purified human hepatic alkaline phosphatase(AP). Treatment started at age of two weeks and was repeated in weekly intervals until death (10 weeks).Samples of AP were diluted with 1 0 ml of physiological saline and infused over a time span of 30 minutes via an umbilical arterial catheter.No toxic or allergic side effects were 0bSe~ed. Serum-AP increased from 3 mU/ml before treatment t o a maximum level of 195 mU/ml with a half -life time between 37 and 62 hours.Urinary excretion of phosphoethanolamine (PEA) decreased under therapy from a maximal value of 9.5 to 5.5 p n~o V m g creatinine (normal: < 0.4).Calcium,phosphorus, parathomne and 1-25 dihydroxyvitamin D levels were within the normal range during therapy.
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Sequential radiographic studies showed no improvement of bone mineralization under therapy. Bone morphology was studied by light and electron microscopy before treatment and post monem. In conmast t o previous studies an unusually woven bundle bone structure was found with abrupt mineralization fronts without ostwblast-like cells.We conclude that this enzyme, substituted for the first time, altered PEA concentnrions but failed to influe~~ct: d~e initial abnormal bone structure of this inf:rnt. Over a ten years period 60 children with osteogenesis imperfecta (O.J.)were studied.15 patients were classified as type I showing a clinically mild disease. 45 patients presenting with O.1.at birth could be subdivided into group A(23) with "broad bone" type femurs and into group B(22) with "thin bone8'type femurs on neonatal radiographs.Group A and to a lesser extent group B showed significantly more skeletal abnormalities than type I. Starting from birth the annual incidence of fractures was high,however at a different level in group A and B and significantly declined after the age of 5 years. In contrast type I showed a peak of fractures at the age of 5 years. A considerable reduction in height and weight during the first 5 years was observed in group A(-8 SD) and to a lesser extent in group B(-4 SD). Type I did not develop significant short stature. All patients showed a typical centrifugal body fat distribution. Cardlac malformations and kidney stones were important extraskeletal manifestations of 0.1. showing an incidence of 10%. IGFI levels were low, normal or slightly subnormal indicating normal growth hormone status. 60% of the retained glucose is utilized by human placenta itself (Schneider et a1.1981) .In diabetic mothers,the macrosomia of the neonate and the placenta can be related to hyperglycemic conditions with functional fetal hyperinsulinism.We studied the influence of hypo-and hyperglycemic conditions in human placenta in vitro. METH0DS:The brutto glucose utilization(bU'G) and the lactate production (bPIL),the lactate utilization(U'L) and the glucose production (P'G) out of traced L-(U-14C) lactate were determined in explants of term placentae(600 mg)incubated for 120 min. RESULTS:l.With a qlucose concentration from 100 to 500 mg/dl,the bU'G shows significant linear increase(from 3.2751.9 to 10.65 1.5 wmol/h/g placenta,? + SD). Under hypoglycemic conditions, bP'L was low and U'L elevated related to euglycemia.Increasing hyperglycemia did not increase bP'L furthermore,but U'L.Phosphoenolpyruvate carboxykinase (PEP-CK), a gluconeogenic key enzyme,was reduced to 40% by 400 vs. 100 mg/dl qlucose concentrations. There are almost no data on endogenous glucose production rate (EGPR) and glucose appearance rate (Ra gluc) in preterm infants of diabetic mothers (idm).
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METABOLIC AND ENZYMATIC INFLUENCE OF GLUCOSE SUPPLY
Therefore we studied 5 preterm and 8 term idm's within the first 24 h after birth (mean 8 h ) . Ra gluc and EGPR were measured, prior to oral feeding, with the prime-dose constant-rate infusion technique, using 6,6-dideuteroglucose. To prevent hypoglycaemia all infants received a low dose glucose i.v. (mean 3.4 mg/kg/min) Results are shown in the There are no significant differences in EGPR and Ra gluc between preterm and term idm's. In preterm idm's EGPR is lower than reported ~. p r r m a t u r r . Plasma and red blood cell (RBC) tocopherol isomer concentrations were determined serially in 35 premature infants (26-34w gestation) from birth to 6 weeks of sge. Blood samples (0.51111) were collected shortly following birth and thence twice weekly in conjunction with samples obtained for clinical manlgement. Plasm? and RBC tocopherol isomers were separated using high pressure liquid chromatography. Following birth, plasma total tocopherol concentration was 0.07 2 0.05mgldl. This concentration increased to 0.35 + 0.24mgldl by week 6 (range 0.08-0.56). The normal adult plasma tocopherol range in Southampton is 0.63-1.24mgldl. RBC total tocopherol concentration was 0.15 + 0.11 at 24h. This concentration increased to0.22 + 0.18mgldl (range 0.14-0.46msldl) by wesk 6 of the study. Normal -adult range of RBC tocopherol was determined to be 0.20-0.39mg/dl. In the majority of the infants over 90% of the vitamin E present in pl?sma rnd RBC was a-tocopherol. It is concluded from these results that although preterm infzints had abnormally low plasma tocopherol concentrations at birth snd did not achieve normal levels within 6 weeks, they may not in fact be vitamin E deficient on the basis of their RBC t-oconherol concentrations.
